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Abstract
The long-term fate of stem cells after intramyocardial delivery is unknown. We used noninvasive, repetitive PET/CT imaging
with [
18F]FEAU to monitor the long-term (up to 5 months) spatial-temporal dynamics of MSCs retrovirally transduced with
the sr39HSV1-tk gene (sr39HSV1-tk-MSC) and implanted intramyocardially in pigs with induced acute myocardial infarction.
Repetitive [
18F]FEAU PET/CT revealed a biphasic pattern of sr39HSV1-tk-MSC dynamics; cell proliferation peaked at 33–35
days after injection, in periinfarct regions and the major cardiac lymphatic vessels and lymph nodes. The sr39HSV1-tk-MSC–
associated [
18F]FEAU signals gradually decreased thereafter. Cardiac lymphography studies using PG-Gd-NIRF813 contrast
for MRI and near-infrared fluorescence imaging showed rapid clearance of the contrast from the site of intramyocardial
injection through the subepicardial lymphatic network into the lymphatic vessels and periaortic lymph nodes.
Immunohistochemical analysis of cardiac tissue obtained at 35 and 150 days demonstrated several types of sr39HSV1-tk
expressing cells, including fibro-myoblasts, lymphovascular cells, and microvascular and arterial endothelium. In summary,
this study demonstrated the feasibility and sensitivity of [
18F]FEAU PET/CT imaging for long-term, in-vivo monitoring (up to
5 months) of the fate of intramyocardially injected sr39HSV1-tk-MSC cells. Intramyocardially transplanted MSCs appear to
integrate into the lymphatic endothelium and may help improve myocardial lymphatic system function after MI.
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Introduction
Stem cell therapy has shown promise in patients with acute
myocardial infarction (MI) or chronic ischemia [1]. However, the
mechanisms by which cells transplanted into the myocardium
provide benefits are not well defined, in part, because the long-
term fate of injected cells is unknown. Understanding the
dynamics of cell trafficking and the long-term rates of cell survival
and engraftment is essential for determining the mechanisms of
cell therapy. Although clinically applicable imaging modalities are
available for monitoring cardiac cell-based therapy [2–4], each has
inherent disadvantages for studying the long-term fate of
transplanted cells. Direct labeling of cells for single photon
emission computed tomography (SPECT) and positron emission
tomography (PET)/computed tomography (CT) is limited by the
physical decay and biologic clearance of the radionuclide used
[5,6]. Paramagnetic contrast agents and supramagnetic nanopar-
ticles for magnetic resonance imaging (MRI) not only have the
disadvantage of biologic clearance, but they can also be
sequestered in other cell types, limiting the duration of monitoring
and increasing false positive results. A new approach—reporter
gene imaging—has distinct advantages over direct labeling of cells.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e22949The reporter is expressed only in living cells and passes on to
daughter cells during proliferation, so the rate of radiolabel decay
or loss of nanoparticles from the labeled cells is not an issue.
Moreover, this approach allows for repetitive imaging with PET or
SPECT over months to years.
Herpes virus type 1 thymidine kinase (HSV1-tk) and its substrate-
specific mutant derivatives sr39HSV1-tk [7] or A168H-HSV1-tk [8]
havebeenwidely usedinreportergene imaging [9–11].TheHSV1-
TK reporter enzyme phosphorylates the radiolabeled nucleoside
analogues (FHBG, FEAU, or FIAU) that are trapped inside the
HSV1-tk transduced cell but not in nontransduced cells [12–15].
After intravenous administration of a radiotracer, the cells can be
detected noninvasively by PET or PET/CT imaging. This reporter
gene imaging approach with PET/CT has been used recently in
clinical studies in human patients, including imaging of sr39HSV1-
tk-based gene therapy of cancer [16] and track the localization of
sr39HSV1-tk transduced T cells [17]. We [18,19] and others [20]
have shown the efficacy of PET imaging of HSV1-tk reporter gene–
expressing stem cells in preclinical studies [18–20], including studies
of short-term stem cell fate after intramyocardial injection in rodent
models of MI [21–23], mesenchymal stem cells (MSCs) implanted
in pig hearts [24,25], and adenoviral-mediated HSV1-tk gene
expression in pig hearts [26] demonstrating that this technology can
be used in a large animal model. However, long-term (several
months), repetitive imaging studies on the spatial and temporal
dynamics of stem cells injected into the myocardium, their
trafficking and engraftment, and persistence of stem cell–derived
tissues have not been reported yet.
In this study, we have demonstrated the feasibility and sensitivity
of [
18F]FEAU PET/CT imaging for long-term in vivo monitoring
(up to 5 months) of MSCs expressing the sr39HSV1-tk reporter
gene after NOGA-guided transendocardial injection in a pig model
of MI. We haveassessed the biodistribution, survival, and long-term
engraftment of transplanted cells and found that transplanted cells
exhibit a biphasic distribution pattern in the heart, peaking in the
infarct region at 4 to 5 weeks after delivery. Furthermore,
transplanted cells appear to engraft as lymphovascular endothelial
cells in myocardial lymphatic vessels and lymph nodes.
Results
Isolation, expansion, and characterization of pig MSCs
and MSC-SR39TK
After isolation, the bone marrow–derived pig MSCs were
expanded in vitro for 2–3 weeks. The adherent, spindle-shaped
MSCs expressed CD44, CD90, and the pig-specific SLA1 antigen,
but were negative for the pan-hematopoietic marker CD45 and the
endothelial marker CD31 (Fig. 1A). There were no significant
morphologic differences in the MSCs before and after retroviral
transduction with the sr39HSV1-tk reporter gene. MSCs from the
2nd passage were used to assess their capacity to differentiate into
bone and fat cells. The MSCs differentiated along both the
adipogenic pathway (oil red staining) and the osteogenic lineage
(alkaline phosphatase activity) (Fig. 1B). The sr39HSV1tk-MSCs
demonstrated similar differentiation abilities. In addition to CD90,
the pig MSCs expressed the lymphoendothelial markers LYVE-1
and VEGFR-3 (Fig. 1C), enabling them to respond to lymphan-
giogenic stimuli. Approximately 43% cells expressed CCR7
(Fig. 1D), enabling them to respond to inflammatory stimuli.
In vivo imaging for sr39HSV1-tk-MSC tracking,
engraftment, and retention
No procedural complications occurred in any pig during any
procedure, including death, cardiac perforation, ventricular
fibrillation, or tachycardia. Group I pigs (negative control; n=3)
were injected with nontransduced autologous MSCs. No specific
accumulation of [
18F]FEAU was observed anywhere in the heart
(average standardized uptake value [SUV], 0.3260.04) or in any
other tissues, except for the kidneys and bladder, which are
involved in the excretion of [
18F]FEAU from the body. Overall,
the biodistribution of [
18F]FEAU in normal pigs appeared to be
similar to that observed by us in rhesus macaques [27].
In Group II pigs (positive control; n=2), sr39HSV1tk-Wi-38
cells (Wi-38 murine fibroblasts transduced with sr39HSV1-tk
reporter gene) were used for intramyocardial injections. The level
of sr39HSV1-tk expression in the sr39HSV1tk-Wi-38 cell line was
very high, as inferred by the level of LNGFR coexpression
(Fig. 2A) and the rapid [
3H]FEAU accumulation observed in in
vitro studies (influx rate Ki=0.9060.05 ml/g/min; Fig. 2B).
Consequently, high levels of [
18F]FEAU accumulation (SUV,
2.460.3) were observed in the area of cell injections into the left
ventricular apical septum (Fig. 2C–G). To confirm that the
sr39HSV1tk-Wi-38 cells were responsible for the increased FEAU
signal detected in the myocardium, the pigs were euthanized 1 day
after the [
18F]FEAU PET/CT imaging study to obtain tissues for
histopathologic analyses of the injection sites. Sr39HSV1tk-Wi-38
cell deposits were clearly identified in the myocardial tissue at the
sites of injection (Fig. 2H), confirming the source of strong signals
in [
18F]FEAU PET/CT images.
In Group III pigs (test group; n=3), 10
8 sr39HSV1tk-MSCs
(autologous porcine MSCs transduced with sr39HSV1-tk reporter
gene) were used for intramyocardial injections. The sr39HSV1tk-
MSCs exhibited moderate levels of sr39HSV1-tk expression as
measured by coexpression of LNGFR (52–64% cells; Fig. 3A) and
in vitro accumulation of [
3H]FEAU (influx rate Ki=0.3460.05 ml/
g/min; Fig. 3B). In 2 pigs, [
18F]FEAU PET/CT imaging studies
were performed at 4 hours, and 7, 21, and 35 days after
sr39HSV1-tk-MSC injection (Figs. S1 and S2); the 2 pigs were
euthanized for histopathologic analyses of cardiac and extra-
cardiac tissues on day 35 after the last imaging. The third pig was
imaged with [
18F]FEAU PET/CT at 6 hours and 2, 6, 20, 33, 64,
106, and 148 days after MSC injection into the left ventricular
apical septum (Fig. 3C,D) and then euthanized on day 150.
The vascular anatomy and anatomic orientation of the heart
inside the thorax differ in humans and pigs [28,29]. Because the pig
heart hangs morevertically withinthe thorax,the axial imagesofthe
apex (Fig. 3E,F; slices 1–4) are formed almost entirely by the left
ventricle. Therefore, to simplify the description ofPET/CT imaging
results in Figure 3, we have provided a schematic diagram showing
the anatomic relationship between the left and right ventricles (thick
ovals) and the atria (thin ovals) (Fig. 3F; first column) for each of the
image planes shown on the cross-sectional model of the heart
(Fig. 3E). The corresponding 12-hour clock coordinates were used
to demarcate the localization of the imaging signals.
The results of repetitive PET/CT imaging of the pig monitored
for 148 days after injection of sr39HSV1-TK-MSC are presented in
detailinFigure3; the resultsobtained inthe other 2 pigsmonitored
for 35 days are presented in the supplementary materials (Figs. S1
and S2). The initial site of sr39HSV1-tk-MSC injection into the
apical septum of the left ventricle (Fig. 3C,D) was clearly
identifiable in all animals on [
18F]FEAU PET/CT images obtained
at 6 hours after sr39HSV1-tk-MSC injection (Fig. 3F,6hc o l u m n ,
slices 1–5, signal in the center). At 6 hours after intramyocardial
injection, the sr39HSV1tk-MSCs were already clearly detectable in
theareaofinfarct(Fig.3F,6 hcolumn,slices4–8,at11to1o’clock)
and in the area of the posterior interventricular sulcus and vena cava
(6 h column, slices 8–12, at 7 o’clock). At 2–6 days after sr39HSV1-
tk-MSC injection, the [
18F]FEAU signal rapidly decreased in all
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However, from days 6 to 33 after injection, the [
18F]FEAU signal
graduallyincreased bothat the initial site of injection(Fig.3F,6,20 ,
and 33-day columns, slices 1–5, central area) and at the anterior
portionofthe septumadjacent to the periinfarctarea(Fig.3F,6,20 ,
and 33-day column, slices 6–8, diagonally from the center to 1
o’clock); this effect was noted in all animals in this group. Two
months after sr39HSV1-tk-MSC injection (Fig. 3F, 64-day
column), the intensity of the [
18F]FEAU signal decreased again
dramatically in many areas of the heart, but was still clearly
detectable at the injection site (Fig. 3F, 64-day column, slices 1–5,
center), the anterior part of the septum adjacent to the infarct area
(slices 6–10, diagonally from the center), in the area of the infarct
(Fig. 3F, 64-day column, slices 6–8, 1 o’clock), the posterior
interventricular lymphatic sinus (Fig. 3F, all days, slice 12, 7
o’clock), and the periaortic lymph nodes (Fig. 3F,3 3a n d6 4 - d a y
column, slice 12 and 13 at 6 o’clock) The [
18F]FEAU activity in
these areas was stable or had minimally decreased during the
subsequent 4 months (Fig. 3F, days 106 and 148). The dynamics of
[
18F]FEAU accumulation in the sr39HSV1-tk-MSC injection sites
was quantified (Fig. 3G);[
18F]FEAU SUV was measured in the
anterior septum, the left ventricular wall region of the infarct, and in
theareaoftheposteriorinterventricularlymphaticsinus(Fig.3F,al l
days, slice 12, 7 o’clock). Figure 3H shows a representation of the
observed pattern of sr39HSV1-tk-MSC distribution from the
injection site to the periinfarct region and to the base of the heart.
In all 3 pigs in Group III, at different days after intramyo-
cardial injection of sr39HSV1tk-MSCs, the [
18F]FEAU activity
was also observed in the periaortic lymphatic structures at the base
of the heart and in the left and right coronary trunks (Fig. 4A–C),
a finding that is consistent with the anatomy of the pig cardiac
lymphatic system [30,31]. In 2 pigs, the [
18F]FEAU activity was
also observed in the cervical lymph nodes, indicating the presence
of sr39HSV1tk-exprerssing cells (Fig. 4D; Fig. S3).
Histologic and immunohistochemical studies
Histopathologic and immunohistochemical (IHC) analyses of
myocardial tissue sections obtained at 35 days after injection of
sr39HSV1tk-MSCs demonstrated large numbers of sr39HSV1-tk-
MSC–derived cells at the interface of scar and the myocardial
Figure 1. Characterization of porcine MSCs and sr39HSV1-tk-MSCs. (A) Expression of CD44, CD45, CD90, porcine SLA1, and CD31 in isolated
MSCs, confirming the MSC nature of the cell population. (B) Morphology of porcine MSCs before and after sr39HSV1-tk reporter gene transduction is
similar (baseline). These MSCs can be differentiated along the adipogenic lineage (oil-red O staining, left column) and the osteogenic lineage (alkaline
phosphatase activity, right column). (C) The MSCs express LYVE-1 (green) and VEGFR-3 (red) in all cells, Hoeschst 33342-stained nuclei (blue), and (D)
CCR7 (green) in approximately 43% cells (FACS).
doi:10.1371/journal.pone.0022949.g001
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[
18F]FEAU signal in the periinfarct regions observed with PET/
CT 33–35 days after cell injection. The sr39HSV1-TK positive
cells were present in the myocardial lymphatic vessels and the peri-
aortic lymph node (Fig. 5C,D), which was also consistent with
[
18F]FEAU PET/CT imaging results (Fig. S4), and in the cervical
lymph nodes (Fig. S3). The %HSV1-tk+ cells ranged from 2% in
the periphery of the periinfarct zone to 79612% in the areas
adjacent to the developing scar (i.e., Fig. 5A,B); lymphatic
microvessels within the area of the scar had segments developed
from almost 100% HSV1-tk+ cells (as seen in Fig. 5C, E, and F);
and the lymph nodes contained 6468% HSV1-tk+ cells (Fig. 5D).
IHC staining for the lymphovascular-specific marker LYVE-1
revealed an extensive network of lymphatic microvessels inside the
developing scar tissue (Fig. 5E). Dual IHC staining for LYVE-1
and sr39HSV1-TK demonstrated multiple dual-labeled lympho-
vascular endothelial cells in the infarct region and the remote areas
of myocardium (Fig. 5F). Dual IHC staining of myocardial tissue
sections with antibodies for anti-HSV1-TK and anti-aSMA
demonstrated the coexpression of these proteins in sr39HSV1-tk-
MSC–derived fibromyoblasts (Fig. S4). These findings demon-
strate that sr39HSV1tk-MSCs integrated into the developing
fibrovascular tissue and lymphatic vasculature.
IHC analysis of myocardial tissue samples obtained 150 days
after the sr39HSV1-tk-MSC injection confirmed the presence of
sr39HSV1-tk-MSC–derived cells in the regions corresponding to
sites of [
18F]FEAU accumulation in PET/CT images. Sr39HSV1-
tk-MSC–derived cells were observed within fibrous connective
tissue of the postinfarct scar, as well as dispersed within
microvascular, lymphovascular, and arterial endothelial cells
(Fig. 5G–J).
Cardiac MRI lymphography
The pathways of lymphatic outflow from the site of sr39HSV1-
tk-MSC injection were mapped in the one pig in Group IV.I n
this pig, after creation of the infarct, the PG-Gd-NIRF813 contrast
agent was injected into the left ventricular apical septum by using
NOGA electromechanical mapping in a manner similar to the
injection of sr39HSV1tk-MSCs (Fig. 6A,B). Two hours after
injection of PG-Gd-NIRF813, the pig underwent in vivo MR
imaging. T1-weighted MRI (1.5T) revealed contrast enhancement
of the injection site and the epicardium-pericardium; contrast
enhancement was especially prominent at the anterior interven-
tricular sulcus, the periaortic lymph nodes, and the area at the
base of the heart (Fig. 6C). These findings are consistent with the
anatomy of the lymphatic system of a porcine heart. At 24 hours
Figure 2. In vitro characterization and in vivo [
18F]FEAU PET/CT of sr39HSV1tk-Wi-38 cells. (A) The level of LNGFR and HSV1-TK co-
expression in sr39HSV1tk-Wi-38 (purple) non-transduced Wi-86 fibroblasts (green). (B) Accumulation of [
3H]FEAU over time in sr39HSV1tk-Wi-38 cells
in vitro (influx rate Ki=0.9060.05 ml/g/min) reflects a very high level of sr39HSV1-tk reporter gene expression in this cell population. (C,F) NOGA
maps indicating sites of injection of sr39HSV1tk-Wi-38 cells (brown dots). (D) Coronal, (E) sagittal, and (G) axial PET/CT images of the pig thorax
obtained 1 hour after [
18F]FEAU administration and 6 hours after intramyocardial injection of sr39HSV1tk-Wi-38 cells clearly demonstrate the
localization of cells injected into the myocardium. (H) H&E stained section of myocardium showing deposits of sr39HSV1tk-Wi-38 cells in the area of
injection (arrows).
doi:10.1371/journal.pone.0022949.g002
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increased intensity of contrast enhancement of the epicardium-
pericardium of the whole heart, the periaortic lymph nodes
(Fig. 6D), and the infarcted region. The pig was euthanized
28 hours after contrast injection, and high resolution ex vivo MRI
(4.7T) of the excised heart was performed to validate the results of
in vivo MR imaging (Fig. 6E,F). Ex vivo MRI confirmed the
distribution of the contrast agent from the site of injection into the
infarcted region and through the subepicardial network of
lymphatic microvessels into the anterior and posterior interven-
tricular lymphatic trunks, the left and right coronary lymphatic
trunks, the main coronary lymphatic trunk, and the periaortic
lymph nodes (Figs. S5, S6).
Near-infrared fluorescence imaging
Near-infrared fluorescence imaging of the dissected heart (in the
one pig from Group IV) confirmed the pattern of distribution of
contrast agent seen with ex vivo and in vivo MRI (Fig. 6G–I). The
contrast agent was distributed at the site of injection, the
myocardial lymphatic system, and the periaortic lymph nodes.
Echocardiography
Cardiac contractile function was measured by echocardiogra-
phy in 2 pigs from the test group (Group III) after sr39HSV1-tk-
MSC injection (Tab. 1). There were no substantial differences in
any parameter between the 2 pigs on injection day. The LVEF
improved by 19% on Day 28 in one pig (#8s210) and by 12% on
Days 21 and 28 in the other pig (#8s211).
Discussion
In the current study, we have demonstrated for the first time the
feasibility of repetitive noninvasive PET/CT imaging with
[
18F]FEAU for long-term monitoring (up to 5 months) of
Figure 3. In vitro characterization and repetitive long-term imaging of intramyocardially injected sr39HSV1-tk-MSC cells with
[
18F]FEAU PET/CT. (A) The level of LNGFR co-expression with sr39HSV1-TK in transduced sr39HSV1-tk-MSC (purple) and non-transduced porcine
MSCs (green). (B)[
3H]FEAU accumulation was moderate in sr39HSV1-tk-MSC (red squares) (Ki=0.3460.03 ml/g/min) but negligible in naı ¨ve pig MSCs
(blue diamonds). (C,D) NOGA maps of sr39HSV1-tk-MSC injection sites into the myocardium. (E) Cross-sectional model of the heart indicating the
image planes numbered on the right. (F)[
18F]FEAU PET/CT images of the pig heart at different time points after intramyocardial transplantation of
sr39HSV1-tk-MSCs. A schematic representation of the ventricles (thick ovals), the atria (thin ovals), and the infarct area (blue) is provided in the left
column. (G) Dynamics of regional [
18F]FEAU accumulation in the injection site (slice 5, blue diamonds), the anterior septum-left ventricular wall region
of infarct (slice 6, red squares), and the aortic lymph node (slice 12, green triangles). (H) Artist’s representation of the observed patterns of sr39HSV1-
tk-MSC distribution from the injection site to the infarct area (blue) and beyond through the myocardial muscle and lymphatic system (arrows).
doi:10.1371/journal.pone.0022949.g003
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acute MI. Our imaging studies showed a biphasic biodistribution
of transplanted cells, with cell proliferation peaking about 34 days
after delivery. Furthermore, our findings indicate that transplanted
MSCs may integrate as lymphatic endothelium, suggesting that
cell therapy with MSCs may provide benefits by facilitating
improvements in lymphatic outflow from the infarct area. This
study lays the groundwork for the clinical translation of reporter
gene technology, which overcomes the limitations associated with
current techniques for monitoring the in-vivo fate of transplanted
cells.
To date, only two groups have reported on successful imaging of
intramyocardially administered MSCs expressing sr39HSV1-tk in
pigs using PET/CT with [
18F]FHBG [24,25]. In a xenotrans-
plantation study, Willmann and colleagues [25] assessed the
efficacy of PET/CT imaging with [
18F]FHBG of adenovirally
transfected human MSCs performed once at 8 hours after open-
chest surgery with direct intramyocardial injection in normal, not
infarcted pigs. The latter xenotransplantation study demonstrated
negative [
18F]FHBG PET imaging results when the MSCs were
injected in PBS, presumably due to a substantial loss of cells from
the injection site. However, when the MSCs were injected in
matrigel, their localization was confined to the site of injection and
could be clearly visualized by [
18F]FHBG PET.
In contrast, the current study in a porcine MI model
demonstrated that retrovirally transduced sr39HSV1-tk-MSCs
suspended in PBS and injected transendomyocardially into the
periinfarct area using NOGA guidance, were clearly detectable in
the injection site 4–6 hours later by [
18F]FEAU PET/CT in all
animals. Our results are in agreement with the report by
Gyongyosi, et al. (2008) [24], which demonstrated that autologous
porcine MSCs lentivirally transduced with truncated HSV1-tk in
fusion with Renilla luciferase and RFP genes were detectable by
[
18F]FHBG PET at 8 hours post NOGA-mediated transendocar-
dial injection into the left ventricular septum. One explanation for
differences in results with Willmann et al, (2009) [25] may be that
autologous pig MSCs have a higher affinity for the inflammatory
and tissue repair milieu in the infarcted pig myocardium as
compared to human MSCs xenotransplanted into the normal
(uninfarcted) pig heart.
In the current study, [
18F]FEAU accumulation at the site of
MSC-tk injection decreased significantly (about 50%) over the first
week after injection in 2 of the 3 animals but was still detectable by
PET/CT. Gyongyosi and colleagues [24] reported detecting a
faint signal in the heart by [
18F]FHBG PET 7 days after injecting a
significantly lower number of cells into two sites into the left
ventricular septum, as compared to the number of cells injected
intramyocardially in our study. Other studies in a porcine model of
MI have demonstrated that only 3% to 11% of intramyocardially
injected stem cells are retained at the injection site or in infarct
areas a few days after delivery [3,32]. In one study [3], after
intramyocardial injection (open-chest surgery) of [
111In]oxine-
labeled autologous peripheral blood mononuclear cells in a
porcine model of MI, only about 11% of cells were retained in
the injection site 1 hour later; most radiolabeled cells were
recovered in the lungs [3]. In our experience using the same
Figure 4. [
18F]FEAU PET/CT images observed in a pig 35 days after intramyocardial injection of sr39HSV1tk-MSCs. PET/CT images of
[
18F]FEAU accumulation in the anterior interventricular lymphatic trunk, AVT (A), the right (B) and left (C) coronary lymphatic trunks (RCT and LCT,
respectively), and the left cervical lymph nodes, CLN (D). The location of aorta (Ao), left atrium (LA), right atrium (RA), left ventricle (LV), and right
ventricle (RV), interventricular septum (SEP), and cervical vertebral body (VRT) are annotated on the images.
doi:10.1371/journal.pone.0022949.g004
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current study (unpublished data), we have recovered an average of
25% (range, 13–41%) of injected cells at the injection site 1 hour
after delivery, as quantified by labeling cells with BioPal - a
europium-containing, nontoxic colloidal lanthanide (BioPhysics
Assay Laboratory, Inc.) that allows for quantitative measurement
of retained cells on the basis of neutron activation of the europium
atoms. The initial rapid decrease of MSC-tk–associated radioac-
tivity observed in the present study is probably due to multiple
factors. After injection, cell loss occurs mostly by venous drainage
to the lungs, as described above [33]; or by subsequent cell death;
backwash from the needle track may account for a small amount
of cell loss as well [3]. Nevertheless, despite the cell loss observed
during the first week after injection, the sr39HSV1tk-MSCs (and
progeny) were still detectable by [
18F]FEAU PET/CT in the site
of injection in all 3 animals at 3 and 5 weeks after injection of the
cells, and in one animal after 2, 3, and 5 months.
Importantly, our studies demonstrated that a large portion
of sr39HSV1tk-MSCs had migrated into the infarcted area
within 4 to 6 hours after intramyocardial injection, and some
sr39HSV1tk-MSCs had migrated through the cardiac lymphatic
vessels into the periaortic lymph nodes and even into the remote
cervical lymph nodes. This trafficking of cells may relate to the
pathophysiologic role of lymph flow in MI. The flow rate of
interstitial lymphatic fluid inside the normal myocardium is at least
10 times greater than that in other tissues, such as lung or skeletal
muscle [34]. The major determinant of myocardial lymph
propulsion is the rhythmic contraction and relaxation of the heart
[35–37]. During MI, the myocardial lymph flow is increased more
than 50% but cannot compensate for the formation of myocardial
edema [38]. Thus, the rhythmic contractions of the heart may push
the injected MSCs along the pathways of increased lymphatic flow
from the infarcted tissue into the anterior and posterior interven-
tricular lymphatic trunks and into the periaortic cardiac lymph
nodes. Moreover, our studies using MRI and near infra-red
flourescence (NIRF) cardiac lymphography after intramyocardial
injection of PG-Gd-NIRF813 suggest that MSCs may rapidly
migrate because of hydrodynamic drag by increased edematous
flow through the enlarged interstitial spaces and via the enlarged
lymphatic channels and vessels, which are hallmarks of MI [38,39].
Figure 5. Tissue analysis. Histopathological and immunohistochemical analysis of tissue samples obtained from the sites of [
18F]FEAU
accumulation in pigs at 35 days (A–F) and 150 days (G–I) after intramyocardial injection of sr39HSV1tk-MSCs. (A) The sr39HSV1-TK positive cells are
densely integrated within the interface of scar and normal-appearing myocardial tissue (magnification6100); (B) Higher magnification (6400) of the
area in panel A identified by a black dotted line. The sr39HSV1-TK positive cells are observed in (C) the vascular-type structures inside the scar tissue,
(D) the anterior interventricular lymphatic vasculature, and (E) peri-aortic lymph node. Expression of lymphovascular-specific marker LYVE-1 (brown)
in the myocardial scar tissue counterstained with hematoxylin (blue). (F) Dual immunohistochemical staining for LYVE-1 (brown) and sr39HSV1-TK
(dark blue) demonstrated sr39HSV1tk-MSCs-derived lymphovascular endothelial cells (arrows) in small and medium-size lymphatic vessels in the
myocardial scar tissue and large pericardial lymphatic vessels next to the scar tissue. (G) Gross images of H&E stained sections of cardiac wall
segments containing post-infarct scar and adjacent myocardial tissues (at 150 days); dotted lines identify areas shown in panels H–J.
Immunohistochemical staining for sr39HSV1-TK expression (brown) is observed in arterial endothelial cells (H), fibromyoblast-like cells (I), and,
occasionally, as striated myofibers (J).
doi:10.1371/journal.pone.0022949.g005
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e22949We, for the first time, provide evidence that transplanted MSCs
delivered directly into the heart after MI can engraft into the
newly developing lymphatic vasculature within the periinfarct
regions and the periaortic nodes. Specifically, histopathologic and
immunohistochemical studies showed large numbers of
sr39HSV1-TK and LYVE-1 positive cells engrafted into the
Figure 6. MR and near infrared fluorescence lymphography with PG-Gd-NIRF813. (A, B) NOGA maps indicate the injection of PG-Gd-
NIRF813 contrast agent in the area of anterior interventricular septum. MR-lymphagraphy images (at 1.5T) were obtained at 2 hours (C) and 24 hours
(D) post intramyocardial injection of PG-Gd-NIRF813. Increased T1 signal was observed in the pericardium, major cardiac lymphatic vessels, periaortal
and mediastinal lymph nodes, as well as in the diaphragmal adhesion (arrows). (E, F) Ex vivo MR imaging (at 4.7T) of the same heart post excision
demonstrated increased signal within the septum corresponding to the location of the myocardial infarction (E – coronal image; F – sagittal image).
(G) Macro photograph of the excised and coronally sectioned heart: LA – left atrium; LV – left ventricle; Ao – aorta; RA – right atrium; RV – right
ventricle. (H) Near infrared fluorescence images demonstrate the correspondence of a bright signal to the injection site and different lymphatic
structures of the heart (arrows). (I) Excised lymph nodes on NIRF images were intensely fluorescent: 1 and 3 - paratracheal; 2 - subaortic; 3 -
paratracheal; 4 - bronchopulmonary; 5 – superior phrenic; 6 - dorsal; 7 - carinal lymph node; 8 - cervical tissue; 9 and 10 - cervical lymph nodes.
doi:10.1371/journal.pone.0022949.g006
Table 1. Echocardiography results.
Pig ID # Days post injection IVS(cm) PW(cm) LVEDD(cm) LVESD(cm) LVEF(%)
#8s210 0 0.8 0.7 3.7 2.7 53
7 0.9 0.8 4.8 3.6 50
21 0.8 0.7 4.4 3.1 57
28 0.6 0.7 4.6 3.1 63
35 0.6 0.7 5 3.7 54
Pig ID # Days post injection IVS(cm) PW(cm) LVEDD(cm) LVESD(cm) LVEF(%)
#8s211 0 1.1 0.6 3.9 2.7 59
7 0.8 0.8 5.1 3.2 67
21 1 0.7 4.9 3.2 66
28 1 0.7 4.7 3.2 66
35 1 0.7 4.9 3.3 60
IVS, interventricular septum; LV, left ventricular; PW, posterior wall of left ventricular; LVEDD, left ventricular end-diastolic dimension; LVESD, LV end-systolic diameter;
LVEF, left ventricular ejection fraction.
doi:10.1371/journal.pone.0022949.t001
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and in some cases in remote cervical lymph nodes at 35 and 150
days after injection. These findings corroborate the results of in vivo
[
18F]FEAU PET/CT imaging studies. This distribution of
transplanted cells may contribute to reconstitution of the function
of the myocardial lymphatic system. The cardiac lymphatic system
shows decreased function after MI that normalizes after
restoration of perfusion [40]. Newly formed lymphatic vessels
contribute to fibrosis and scar formation by draining proteins and
edematous fluid [39]. At the time we injected sr39HSV1tk-MSCs
(1 week after infarction), cardiomyocytes around the newly
forming scar are known to express high levels of vascular
endothelial growth factor (VEGF)-C [39], which may facilitate
the differentiation of sr39HSV1tk-MSCs into lymphatic endothe-
lium. At this point in the healing process, lymphatic drainage
begins to improve in an attempt to resorb the flow of edematous
fluid. Our hypothesis that transplanted MSCs participate in the
lymphatic aspects of cardiac healing is supported by the results of
current in vitro studies demonstrating that pig MSCs express
lymphoendothelial markers LYVE-1, VEGFR-3, and CD-90,
which enable the cells to respond to lymphoproliferative stimuli, as
well as CCR7, a receptor that is crucial for recruitment of
lymphatic endothelial precursors into sites of inflammation and
injury [41]. Conrad, et al (2009) have also demonstrated that
MSCs express CCR7, can acquire a lymphoendothelial phenotype
when exposed to VEGF-C, and can then increase in vivo
regeneration of the lymphatics in a mouse tail model of
lymphedema [42]. Furthermore, our hypothesis is supported by
the data indicating that infusion of hyaluronidase, a well-
recognized lymphagogue, reduces myocardial infarction size by
increasing the myocardial lymph flow rate [34,43–45]. Because
the lymphatic system of the pig heart is similar to that of the
human heart [34], our results may have implications for
understanding the therapeutic effect of intramyocardially admin-
istered MSCs in patients with MI.
After an initial decrease during the first week after injection,
the [
18F]FEAU signal in our study gradually increased. The peak
signal was observed at the site of injection, in the infarcted
myocardium, and in the major cardiac lymphatic vessels and the
periaortic lymph nodes at 30 to 35 days after injection. This
demonstrates that between 2 and 5 weeks after intramyocardial
injection, the surviving MSCs proliferated at the infarct site and
other local areas, yielding stronger signals from the progeny tissue
observed at 33–35 days. Such a pattern of signal intensity is
consistent with a general increased proliferative activity of various
cell types in the myocardium (ie, fibroblasts, neovascular
endothelial cells) during the 3 to 5 weeks after MI [46]. Also,
our findings are in agreement with the report by Quevendo, et al
(2009), in which viable MSCs were identified inside the infarct
and border zones at 12 weeks post transplantation into the
chronic ischemic scar [47]. The presence of large numbers of
sr39HSV1-tk positive cells in the sites of high [
18F]FEAU
accumulation was confirmed by immunohistochemical studies
of myocardial and remote (ie, lymph node) tissues in 2 of 3 pigs
euthanized on day 35 after sr39HSV1tk-MSCs injection. In one
pig, long-term repetitive [
18F]FEAU PET/CT studies conducted
after 1 month showed a gradual reduction of [
18F]FEAU activity
in the sites of sr39HSV1tk-MSCs engraftment at 64, 106, and
148 days after cell injection. This finding suggests a gradual
decrease in the overall inflammation in the infarct and in the
proliferation of different cell types during the later phases of
fibrosis and myocardial scar maturation [46]. Other reasons for
the observed decrease in signal over time may also reflect
immunogenic processes as well as decreasing protein expression.
Nevertheless, [
18F]FEAU PET/CT imaging demonstrated suffi-
cient sensitivity to detect the residual sr39HSV1-tk–expressing
progeny tissues developed from the transplanted sr39HSV1tk-
MSCs. The presence of sr39HSV1-tk positive cells in the sites of
high [
18F]FEAU accumulation was confirmed by immunohisto-
chemical studies of myocardial tissue sections obtained 150 days
after injection.
The long-term persistence of sr39HSV1tk-MSCs–derived
progeny may have significance in terms of the therapeutic
mechanism of intramyocardially injected MSCs. In preclinical
studies, MSCs appear to provide benefits through a paracrine
mechanism. MSCs have been shown to attenuate cardiac fibrosis
by producing HGF [48] and to contribute to angiogenesis by
producing VEGF [49]. Data from our group [50] suggest that
MSC therapy in dogs may increase collagen deposition after MI,
thus fortifying the nascent myocardial scar; MSC-treated dogs
showed less unresolved infarct, with smaller areas of necrosis
surrounded by collagen deposits. Improved healing associated with
cell therapy may involve increased lymphatic function to help
eliminate excess fluids and cells.
In summary, we have demonstrated the feasibility and
sensitivity of [
18F]FEAU PET/CT imaging for long-term
monitoring (up to 5 months) of the in vivo fate of MSCs that
express the sr39HSV1-tk reporter gene after NOGA-guided
transendomyocardial injection in a pig model of Ml. Our in vivo
imaging results were confirmed by immunohistochemical studies in
situ. We found that transplanted MSCs have a biphasic pattern of
spatial and temporal dynamics, with a peak migration (and/or
proliferation) into the infarcted area at 4 to 5 weeks after
intramyocardial injection in to the peri-infarct zone. We have
discovered that MSCs incorporate into the cardiolymphatic system
and into areas of myocardial healing, which has not been
previously reported. We hypothesize that transplanted MSCs
may contribute to the process of myocardial repair by engrafting
into lymphatic vessels within the periinfarct regions and the
periaortic nodes, thus facilitating improved lymphatic outflow
from the infarct. The role of lymphatics in the healing process has
not been extensively studied and warrants further investigation in
light of these findings. Additional imaging and biological studies
are necessary to examine the role of the myocardial lymphatic
system in trafficking of MSCs in the heart.
Methods
Study groups
The protocol of studies in experimental animals number 10-05-
12022 has been approved by the Institutional Animal Care and
Use Committee of the UT MD Anderson Cancer Center,
Houston, TX. Adult pigs Sus scrofa (N=9) were divided into 4
groups. Group I pigs (negative control; n=3) received injections
of nontransduced autologous MSCs. Group II pigs (positive
control; n=2) received sr39HSV1tk-Wi-86 positive control cells
(4–6 injections of 1610
8 in 0.1 ml of PBS per injection into the left
ventricular apical septum). Group III pigs (test group; n=3)
received autologous sr39HSV1-tk-MSC (3 injections of 1610
8
cells in 0.1 ml of PBS per injection into the apical or subcuspidal
area of the left ventricular septum) 7 days after infarction. The one
pig in Group IV (PG-Gd-NIRF813 study group) at day 7 post
infarct received polyglutamic-Gd-DTPA near-infrared fluores-
cence (PG-Gd-NIRF813) contrast agent [51] to map the lymphatic
drainage from the injection site in the myocardium. PG-Gd-
NIRF813 was injected into the same site (1 mg in 0.5 ml saline) as
the sr39HSV1tk-MSCs.
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MSCs
All work was performed under approved Institutional Animal
Care and Use Committee (IACUC) protocols. Briefly, 10–20 ml of
bone marrow was aspirated under local anesthesia from the iliac
crest of pigs (weighing about 100 kg each) 30 days before imaging
experiments. The aspirates were heparinized and centrifuged at
8006g for 10 min at room temperature; the serum was discarded.
The cells were diluted 1:1 with phosphate-buffered saline (PBS),
layered over an equal volume of Ficoll (1.077 g/mL, Techno-
clones), and centrifuged at 8006g for 30 min. Mononuclear cells
recovered from the buffy coat at the gradient interface were
washed twice with PBS (3006g for 5 min at room temperature).
Cells were seeded at 2610
5/cm
2 in alpha modified Eagle’s
medium (aMEM) (Gibco) with 20% fetal bovine serum (FBS)
(Gibco). The cells were then cultured at 37uCi n5 %C O 2 in air,
and nonadherent cells were removed after 5 days. The culture
medium was replaced every 3 to 4 days. After about 7 days, when
isolated colonies of pig MSCs were apparent, the cells were
trypsinized and replated at 8000/cm.
2 Immunophenotyping of
MSCs was performed by using the following human antibodies
conjugated with fluorescin isothiocyanate (FITC) or phycoerythrin
(PE): CD44, CD90, pig SLA1, CD31, and CD45 (Becton-
Dickinson); VEGFR-3/Flt-4 and CCR7 (R&D Systems); uncon-
jugated LYVE-1 rabbit antibody (AngioBio) was recognized by a
secondary AlexaFluor-488-conjugated goat-anti-rabbit antibody
(Invitrogen). Human-IgG1-FITC, and IgG1-PE were used as
isotype controls. In addition, pig MSCs (pre- and post-viral
transduction) were subjected to both adipose and bone lineage
differentiation assays as described previously [52]. Collectively,
these data confirmed the MSC nature of this cell population.
Fluorescence-activated cell sorting (FACS) was performed using
FACSAria (BD Biosciences) and fluorescence microscopy using
BX51 (Olympus).
Transduction of Porcine MSCs
Stock MND-sr39HSV1tk-LNGFR retroviral producer cells [53]
(1610
7 PFU/ml) were grown to 70% confluence at 37uC; the
producerlineswereplacedat32uC,andsupernatantswerecollected
the next morning. Porcine MSCs(approximately 3610
6/flask) were
washed once in PBS, and fresh MND-sr39HSV1tk-LNGFR virus
supernatants were added to each T175 flask, together with 8 mg/ml
of polybrene. The cultures were rocked slowly overnight, and this
process was repeated the next morning with fresh retrovirus-
containing supernatant at 32uC. The MSCs were transduced with
the retrovirus within the first 4 passages after isolation and initial
plating. At 48 hours after transduction, the MSCs were analyzed by
flow cytometry for transduction efficiency by using anti-human
LNGFR monoclonal antibody (LN-12; Boehringer Mannheim).
Transduced MSCs expressing high levels of the LNGFR reporter
gene were designated as sr39HSV1tk-MSCs.
Sr39HSV1tk-Wi-38 control cells
The Wi-38 murine fibroblasts (from ATCC) were stably
transduced with the MND-sr39HSV1tk-LNGFR described above
by using Fugene (Roche Applied Science), according to the
manufacturer’s protocol. After antibiotic selection, the remaining
cells were sorted via FACs for high expression levels of LNGFR
cell surface reporter, and individual clones were isolated. We
selected the clone #86 for coexpression of very high levels of both
LNGFR and high sr39HSV1-TK enzyme activity, as described
previously. This clone, designated sr39HSV1tk-Wi-38, was grown
in DMEM 10% FCS.
In vitro [
3H]FEAU accumulation assay
Assessment of radiotracer uptake and accumulation was
performed as described previously [8,14]. Briefly, the
sr39HSV1tk-MSCs cells were plated in duplicate in 150-mm
dishes and grown until about 50% confluent. Then, the culture
medium was replaced with 14 mL of medium containing
radiotracers [
3H]FEAU 3.7 kBq/mL (Moravek). The cells were
incubated in the [
3H]FEAU-containing medium for 15, 30, 60,
and 120 minutes before scraping the monolayers, transferring the
content into 15-mL tubes, and centrifuging at 10006g for
2 minutes. A 100 mL aliquot of supernatant was transferred to a
pre-weighed scintillation tube, and the rest was removed by
aspiration before snap-freezing the cell pellet on dry ice. The
frozen pellets were transferred to pre-weighed scintillation vials
and weighed again to calculate the weight of the cell pellet. The
frozen pellets were transferred to pre-weighed scintillation vials,
weighed, thoroughly dissolved in 0.5 mL of Soluene-350 for
24 hours, and mixed with 5 ml of scintillation cocktail Ultima
Gold (Perkin Elmer). Radioactive b-emissions were measured
within pre-calibrated energy ranges by using a scintillation counter
Packard Tri-Carb 3100TR (Perkin Elmer) to quantify the
[
3H]FEAU and were normalized by the cell pellet weight to
calculate the radioactivity concentration (dpm/g). Radioactivity
concentration in cell pellets was divided by that of the medium
[(dpm/g cells)/(dpm/g medium)] and plotted against time. A
linear regression analysis (regression slope) was used to calculate
the rate of [
3H]FEAU accumulation in cells, which is proportional
to the level of sr39HSV1-tk gene expression.
Porcine model of acute myocardial infarction
This model has been described previously [54,55]. Briefly, a
catheter was advanced through the aortic valve into the left
ventricular cavity. Aortic and ventricular pressures were recorded.
A left ventriculogram was performed in a 30u RAO projection by
using a controlled injection of 30 ml of a nonionic, iso-osmolar
contrast agent (Visipaque, GE Healthcare) at a constant rate of
10 ml/sec. A 6F coronary guiding catheter was advanced through
the aorta and was selectively engaged into the left coronary ostium.
Angiograms were performed at the predetermined projections:
PA, 30u LAO, and 30u RAO. A floppy 0.0140 coronary guide wire
was positioned at the distal third of the left anterior descending
artery. An angioplasty balloon approximately the same size as the
artery was placed and was inflated to nominal pressure. Contrast
was injected to ensure the complete occlusion of the distal bed and
the patency of the diagonal branch. The balloon remained inflated
for approximately 90 minutes and then was deflated to allow for
passive reperfusion. The pig was transferred to the ICU for
monitoring.
NOGA-mediated transendomyocardial injection of
sr39HSV1-tk-MSC or sr39HSV1tk-Wi-38 cells
Nonfluoroscopic electromechanical mapping has been de-
scribed [54]. Briefly, an 8F NOGA Myostar catheter (Cordis)
was introduced through the left femoral sheath 7 days after MI,
and left ventricular electromechanical mapping was performed.
Mapping points were captured by measuring the unipolar voltage
of the endocardium to construct a 3D representation of the left
ventricle. During the procedure, brief (,3 s) nonsustained
ventricular tachycardia was observed in some pigs and was
attributed to irritation of the left ventricular endocardium from
catheter navigation. The NOGA injection catheter was prepared
by adjusting the needle extension at 0u and 90u flex. The injection
catheter tip was placed across the aortic valve and into the apical
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injection.
PET/CT imaging with [
18F]FEAU
The synthesis of [
18F]FEAU has been described [56,57]. [
18F]-
FEAU was administered intravenously at a dose of
11.9961.79 mCi/animal. Repeat PET/CT imaging studies were
performed on a GE Discovery ST-8 PET-CT scanner (GE
Healthcare). A conventional, noncontrast CT scan (300 mA;
120 kVp; 0.5 sec X-ray tube rotation, table speed, 13.5 mm/
rotation) was acquired. Then, dynamic PET images of the thorax
were acquired in 2-dimensional mode following the administration
of 16 mCi of [
18F]FEAU for a period of 0–40 min. This was then
followed by two whole body PET images acquired at 40 and
60 min post [
18F]FEAU administration using 4 bed positions,
5 min each. PET images were reconstructed by using VUE Point
reconstruction software (GE Healthcare), which uses an ordered
subset expectation maximization (OSEM) algorithm. Emission
data were corrected for attenuation scatter (with the use of CT),
random events, and dead-time losses by using manufacturer’s
software. The CT and PET data were transferred to a dedicated
imaging analysis workstation (Hermes Browser, Version 3.0,
Hermes Medical Solutions). The PET/CT images were re-
oriented to match the cardiac apex and to align the cardiac axis
using the rib cage (CT images) as an external anatomical reference
using the Hybrid Viewer software module (Hermes). Images were
cross-normalized by using the Volume Display Program, Version
1.2 (Hermes) to accurately compare images obtained at different
days of the study. Circular regions of interest (ROI) were placed in
the areas with the highest radioactivity and in the muscle tissue
with a low level of activity. Maximum SUV was calculated from
each ROI by using the following formula: SUV=measured
activity concentration (Bq/g)6body weight (g)/injected activity
(Bq). For the assessment of radioactivity accumulation in the lungs,
the lung area in each transaxial plane on the PET image was
outlined manually on the basis of corresponding MRI and/or CT
images.
Echocardiography
Myocardial contractile function was assessed by using echocar-
diography on the day of [
18F]FEAU PET/CT, as previously
described [58,59]. The heart was imaged in the 2D mode in the
short-axis view of the left ventricle at the level of the papillary
muscle. The left ventricular ejection fraction was obtained
according to the American Society of Echocardiography leading-
edge method from at least 3 consecutive cardiac cycles [60].
Similar studies with [
18F]FDG and ultrasound in a pig model of
MI have been reported previously [61].
In vivo MR imaging
MRI lymphography with polyglutamic-Gd-DTPA near-infra-
red fluorescence (PG-Gd-NIRF813) contrast agent was used to
study the role of lymphatic drainage in the trafficking of
sr39HSV1tk-MSCs from the injection site in the myocardium
and persistence of sr39HSV1tk-MSCs in the heart. The synthesis
of PG-Gd-NIRF813 has been described [51,62]. After MI, PG-
Gd-NIRF813 (250 mg in 4 mL PBS) was injected into the same
sites as those described above for MSC injection. PG-Gd-
NIRF813 was injected into the right shoulder for reference.
MRI was performed at 2 hours and repeated at 24 hours after
PG-Gd-NIRF813 injection by using an 8-channel 1.5T whole-
body research MR scanner (Signa HDx; General Electric
Healthcare) with a phased-array coil and both cardiac and
respiratory gating. Fat-suppressed, T1-weighted, Dixon-based
in- and out-of-phase FIESTA cine and double IR imaging were
performed. Fields of view included short-axial and 4-chamber
views of the heart, as well as axial and coronal views of the thorax.
Ex vivo MRI
The heart was resected immediately after in vivo MR imaging,
and ex vivo MR imaging was performed on a 4.7 Tesla GE/Bruker
Biospec scanner. Axial and coronal images were obtained by using
a 100-mT/m, 26-cm-inner-diameter, actively shielded gradient
coil system (285.71 T/m-s slew rate) and a 19.7-cm-inner-
diameter, volume radiofrequency coil. T1-weighted MR images
(TE=10.5 ms, TR=800 ms) were acquired with a
14.5610.87 cm field-of-view coronal and a 1269 cm field-of-view
axial; 2-mm section thickness, 2-mm gap, and a 2566192 matrix.
Ex vivo fluorescence imaging
The resected heart and lymph nodes were imaged by using an
IVIS-200 imaging system (Xenogen Corp.) with ICG filter sets
(excitation/emission, 710–760/810–875 nm). The camera setting
included medium binning (8*) with an F stop of 1. The CDD
resolution was 204862048 pixels; the exposure time was
3 seconds, and the field of view was 13613 cm.
Immunohistochemistry
Control pigs were euthanized 2 days after MSC injections, and
experimental pigs were euthanized at 35 days (n=2) and 150 days
(n=1) after injection. Tissue samples from the regions with high
levels of high [
18F]FEAU accumulation on PET/CT images,
including the heart and the paraaortic and cervical lymph nodes,
were fixed in 2% paraformaldehyde and embedded in paraffin.
Serial paraffin sections were deparaffinized, rehydrated, and
pressure-cooked for 4 min in citrate buffer (10 mM, pH 6.0) for
antigen retrieval. The sections were incubated in 1% H2O2/
methanol and then in 4% goat serum (Abnova). Primary
monoclonal antibodies against HSV1-TK protein (clone 4C8 at
1:50 dilution, from Dr. William Summers, Yale University), CD71
(1:50, Santa Cruz), CD90 (1:50, Santa Cruz), vimentin (1:50,
Santa Cruz), a-smooth muscle actin (aSMA; Santa Cruz), and
LYVE-1 (AngioBio) were used. Secondary antibodies conjugated
to horseradish peroxidase or alkaline phosphatase (Vector, CA)
were used to detect primary antibody reactive tissues and were
stained with 3939-diaminobezidine (DAB) and 5-bromo-4-chloro-
3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT), respec-
tively. Adjacent tissue sections were stained with hematoxylin and
eosin.
Supporting Information
Figure S1 The fate of intramyocardially injected trans-
duced sr39HSV1tk-MSCs monitored over 35 days with
[
18F]FEAU PET/CT in pig #8s210. (A) The level of LNGFR
co-expression with sr39HSV1-TK in transduced (green) and
nontransduced (purple) sr39HSV1tk-MSCs. (B)[
3H]FEAU accu-
mulation over time in sr39HSV1tk-MSCs (influx rate
Ki=0.09260.006 ml/g/min) reflects a moderate level of
sr39HSV1-tk reporter gene expression in this particular cell
population. (C) NOGA maps indicating sites of sr39HSV1-tk-
MSC injection into the myocardium. (D) Dynamics of regional
[
18F]FEAU accumulation (SUV) in the site of stem cell injection
(blue diamonds), the interventricular septum (blue circles), the
paraaortic lymph node(s) (green upward triangles), the proximal
left anterior descending coronary artery region (green downward
triangles), and the infarct area in the anterior left ventricular wall
(red squares). (E) Axial PET/CT images of the heart obtained
Long-Term Imaging of MSCs Implanted into the Heart
PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e229491 hour after [
18F]FEAU administration at baseline and at different
time points after intramyocardial injection of sr39HSV1tk-MSCs
demonstrating the spatial and temporal dynamics of the
sr39HSV1tk-MSCs distribution.
(TIF)
Figure S2 The fate of intramyocardially injected trans-
duced sr39HSV1-tk-MSCs monitored over 35 days with
[
18F]FEAU PET/CT in pig #8s211. (A) The level of LNGFR
co-expression with HSV1-TK in transduced (green) and non-
transduced (purple) sr39HSV1tk-MSCs. (B)[
3H]FEAU accumu-
lation over time in sr39HSV1-tk-MSCs (influx rate
Ki=0.15160.005 ml/g/min) reflects a moderate level of
sr39HSV1-tk reporter gene expression in this particular cell
population. (C) NOGA maps indicating sites of sr39HSV1-tk-
MSC injection into the myocardium. (D) Dynamics of regional
[
18F]FEAU accumulation (SUV) in the site of stem cell injection
(blue diamonds), the interventricular septum (blue circles), the
paraaortic lymph node(s) (green upward triangles), the proximal
left anterior descending artery region (green downward triangle-
s),and the infarct area in the anterior left ventricular wall (red
squares). (E) Axial PET/CT images of the heart obtained 1 hour
after [
18F]FEAU administration at baseline and at different time
points after intramyocardial injection of sr39HSV1tk-MSCs
demonstrating the spatial and temporal dynamics of the
sr39HSV1tk-MSCs distribution.
(TIF)
Figure S3 [
18F]FEAU PET/CT images of cervical lymph
nodes in a pig after intramyocardial injection of
sr39HSV1tk-MSCs. (A) Coronal, sagittal, and axial PET/CT
images of cervical region and (B)[
18F]FEAU accumulation in
cervical lymph nodes at different time points after intramyocardial
injection of sr39HSV1tk-MSCs: points – average SUV for all
positive nodes; bars – standard deviation. (C) The presence of
Sr39HSV1-TK+ cells in cervical lymph nodes was confirmed by
IHC.
(TIF)
Figure S4 Coexpression of sr39HSV1-TK and aSMA in
myocardial tissue sections obtained from a pig at 35
days post intramyocardial injection of sr39HSV1tk-
MSCs. Prominent co-localized expression of sr39HSV1-TK
(A,C,E) and a-SMA (B,D,F) was observed in the periinfarct
areas of myocardium.
(TIF)
Figure S5 Ex vivo T1-weighted MR lymphography of the
excised porcine heart obtained at 28 hours after intra-
myocardial injection of PG-Gd-NIRF contrast. (A) Serial
transaxial T1-weighted contrast-enhanced MR images the same
heart shown in Fig. 6F demonstrating the localization and extent
of myocardial infarct at day 9 post infarct and pathways of
lymphatic outflow (white contrast signals). (B) NOGA maps of
contrast agent injection sites.
(TIF)
Figure S6 Ex vivo T1-weighted MR lymphography of the
excised heart obtained at 28 hours after intramyocardi-
al injection of PG-Gd-NIRF contrast. (A) Serial sagittal T1-
weighted contrast-enhanced MR images of the same heart shown
in Fig. 6E demonstrating the localization and extent of myocardial
infarct at day 9 post infarct and pathways of lymphatic outflow
(white contrast signals). (B) NOGA maps of contrast agent
injection sites.
(TIF)
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